Small-molecule inhibitors of fibroblast growth factor receptor (FGFR) tyrosine kinases (TK)

被引:35
作者
Manetti, F [1 ]
Botta, M [1 ]
机构
[1] Univ Siena, Dipartimento Farmaco Chim Tecnol, I-53100 Siena, Italy
关键词
D O I
10.2174/1381612033391487
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Fibroblast growth factor receptors (FGFR) are members of a family of polypeptides synthesized by a variety of cell types during the processes of embryonic development-and in adult tissues. FGFR have been detected in normal and malignant cells and are involved in biological events that include mitogenic and angiogenic activity with a consequent crucial role in cell differentiation and development. To activate signal transduction pathways, FGFR are coupled to fibroblast growth factors (FGF) and heparan sulfate (HS) proteoglycans to form a biologically fundamental ternary complex. Based on these considerations, a variety of inhibitors able to block the signaling cascade through a direct interaction with FGFR have been designed and investigated for their biological properties related to antiangiogenesis and antitumor activity. The purpose of this review is to focus. on synthetic chemical approaches aimed at blocking tyrosine kinase (TK) receptors, members of the FGFR family. In particular, a literature survey aimed at summarizing,on. the structural properties that a compound should possess to show affinity toward FGFR is presented, and structure-activity. relationships (SAR) on FGFR inhibitors are delined.
引用
收藏
页码:567 / 581
页数:15
相关论文
共 111 条
  • [1] GROWTH-FACTORS AND CANCER
    AARONSON, SA
    [J]. SCIENCE, 1991, 254 (5035) : 1146 - 1153
  • [2] SYNTHESIS AND SECRETION OF VASCULAR-PERMEABILITY FACTOR VASCULAR ENDOTHELIAL GROWTH-FACTOR BY HUMAN RETINAL-PIGMENT EPITHELIAL-CELLS
    ADAMIS, AP
    SHIMA, DT
    YEO, KT
    YEO, TK
    BROWN, LF
    BERSE, B
    DAMORE, PA
    FOLKMAN, J
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1993, 193 (02) : 631 - 638
  • [3] *ANG FDN INC, 1999, ANT THER SELF HELP B
  • [4] 1-oxo-3-aryl-1H-indene-2-carboxylic acid derivatives as selective inhibitors of fibroblast growth factor receptor-1 tyrosine kinase
    Barvian, MR
    Panek, RL
    Lu, GH
    Kraker, AJ
    Amar, A
    Hartl, B
    Hamby, JM
    Showalter, HDH
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1997, 7 (22) : 2903 - 2908
  • [5] Inhibition of FGF-1 receptor tyrosine kinase activity by PD 161570, a new protein-tyrosine kinase inhibitor
    Batley, BL
    Doherty, AM
    Hamby, JM
    Lu, GH
    Keller, P
    Dahring, TK
    Hwang, O
    Crickard, K
    Panek, RL
    [J]. LIFE SCIENCES, 1997, 62 (02) : 143 - 150
  • [6] Kinase insert domain-containing receptor kinase inhibitors as anti-angiogenic agents
    Bilodeau, MT
    Fraley, ME
    Hartman, GD
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2002, 11 (06) : 737 - 745
  • [7] BLANKLEY CJ, 1996, Patent No. 9615128
  • [8] Brem, 1999, Cancer Control, V6, P436
  • [9] Browder T, 2000, CANCER RES, V60, P1878
  • [10] Discovery and structure-activity studies of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors
    Connolly, CJC
    Hamby, JM
    Schroeder, MC
    Barvian, M
    Lu, GH
    Panek, RL
    Amar, A
    Shen, C
    Kraker, AJ
    Fry, DW
    Klohs, WD
    Doherty, AM
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1997, 7 (18) : 2415 - 2420